O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study - G. Dore; J. Grebely; F. Altice; A.H. Litwin; O. Dalgard; E.J. Gane; O. Shibolet; A. Luetkemeyer; R. Nahass; C.Y. Peng; B. Conway; D.M. Iser; et al. (Elsevier, 2017)